{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:42:48Z","timestamp":1791225768033,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.yebeh.2008.08.009","type":"journal-article","created":{"date-parts":[[2008,9,27]],"date-time":"2008-09-27T06:00:11Z","timestamp":1222495211000},"page":"113-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy"],"prefix":"10.1016","volume":"14","author":[{"given":"James W.","family":"McAuley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel F.","family":"Shneker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2008.08.009_bib1","doi-asserted-by":"crossref","first-page":"191S","DOI":"10.1592\/phco.20.12.191S.35250","article-title":"Antiepileptic drug treatment: outcomes and adherence","volume":"20","author":"Garnett","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2008.08.009_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.yebeh.2007.03.014","article-title":"Current approaches to the use of generic antiepileptic drugs","volume":"11","author":"Kr\u00e4mer","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2008.08.009_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.seizure.2005.12.010","article-title":"Are there potential problems with generic substitution of antiepileptic drugs? A review of issues","volume":"15","author":"Crawford","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2008.08.009_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S0317167100051957","article-title":"Generic substitution for brand name antiepileptic drugs: a survey","volume":"27","author":"Guberman","year":"2000","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.yebeh.2008.08.009_bib5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.yebeh.2004.05.011","article-title":"Therapeutic equivalency of generic antiepileptic drugs: results of a survey","volume":"5","author":"Wilner","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2008.08.009_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yebeh.2005.04.005","article-title":"Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy","volume":"7","author":"Haskins","year":"2005","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2008.08.009_bib7","first-page":"499","article-title":"Assessing the needs of pharmacists and physicians in caring for patients with epilepsy","volume":"39","author":"McAuley","year":"1999","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.yebeh.2008.08.009_bib8","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.wnl.0000262876.37269.8b","article-title":"What\u2019s the problem with generic antiepileptic drugs? A call to action","volume":"68","author":"Berg","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2008.08.009_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.yebeh.2008.02.006","article-title":"Strategies to detect adverse effects of antiepileptic drugs in clinical practice","volume":"13","author":"Carre\u00f1o","year":"2008","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505008002643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505008002643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:19:16Z","timestamp":1761502756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505008002643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1525505008002643"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2008.08.009","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2008.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}